Key result
BTK inhibitors are linked to incident AF, complicating anticoagulant selection, bleeding, and drug interactions.
Answers are grounded in this paper and cite their sources.
The development of bruton tyrosine kinase inhibitors (BTKi) has been a significant advancement in the treatment of chronic lymphocytic leukemia and related B-cell malignancies. As experience in using ibrutinib increased, the first drug to be licensed in its class, atrial fibrillation (AF) emerged as an important side effect. The intersection between BTKi therapy for B-cell malignancies and AF represents a complex area of management with scant evidence for guidance. Consideration needs to be taken regarding the interplay of increased bleeding risk versus thromboembolic complications of AF, drug interactions between ibrutinib and anticoagulants and antiarrhythmic agents, and the potential for other, as yet seldom reported cardiac side effects. This review describes the current knowledge regarding BTKi and potential pathophysiologic mechanisms of AF and discusses the management of BTKi-associated AF. Finally, a review of the second generation BTKi is provided and gaps in knowledge in this evolving field are highlighted.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2017) conducted a review in Chronic lymphocytic leukemia and related B-cell malignancies with atrial fibrillation. Bruton tyrosine kinase inhibitors (BTKi) was evaluated. Bruton tyrosine kinase inhibitors are associated with atrial fibrillation, requiring careful management of bleeding risks, thromboembolic complications, and drug interactions.
Synapse has enriched 10 related papers. Consider them for comparative context: